# GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)

> **NCT06309732** · PHASE2 · COMPLETED · sponsor: **Queen Mary University of London** · enrollment: 36 (actual)

## Conditions studied

- Testicular Neoplasms

## Interventions

- **DRUG:** Pegfilgrastim
- **DRUG:** Dactinomycin
- **DRUG:** Methotrexate
- **DRUG:** Etoposide
- **DRUG:** Cisplatin
- **DRUG:** Epirubicin

## Key facts

- **NCT ID:** NCT06309732
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2013-06
- **Final completion:** 2014-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06309732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06309732, "GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06309732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*